Displaying 1 - 20 of 24
| Active Ingredient | GENTAMICIN |
| Therapeutic Class | AMINOGLYCOSIDES |
| Indications | Septicaemia and neonatal sepsis, biliary infections, intraabdominal and UTI, acute pyelonephritis. Severe gram-negative infections, primarily pseudomonas infections. |
| Caution | Increase dose interval in renal impairment in children and the elderly. Use nomogram (see renal disease guidelines p.19-38) and check peak (1 hour) and trough (predose) levels. Nehrotoxicity or ototo More ... |
| Dose Range |
i.m. 3-5mg/kg/day in divided doses every 8 hours for 7-10 days. 12 hours (clearance 30-70 ml/min), 24 hours (clearance 10-30ml/min, 48 hours (clearance 5-10ml/min) |
| Drug Interactions | |
| Pregnancy | Risk of auditory or vestibular nerve damage in the infant when aminoglycosides a More ... |
| Breast Feeding |
| Active Ingredient | TOBRAMYCIN |
| Therapeutic Class | AMINOGLYCOSIDES |
| Indications | Septicaemia and neonatal sepsis, biliary infections, endocarditis, acute pyelonephritis. Tobramycin is slightly more effective for Pseudomonas aeruginosa than gentamicin, but shows less activity agai More ... |
| Caution | Nephrotoxicity and ototoxicity occur with high concentrations. It is less toxic than gentamicin. The dose should be reduced in renal failure and in the elderly. C.f. prescribing in renal disease p. 3 More ... |
| Dose Range |
Adult: 3-5mg/kg/day divided every 8 to 12 hours based on renal function and serum tobramy cin levels: or once-daily administration is 4-7mg/kg/day; higher doses may be needed depending on the diagnosis. Pediatric 1 mth- 12 yrs: 2-2.5mg/kg every 8 hours. |
| Drug Interactions | |
| Pregnancy | Risk of auditory or vestibular nerve damage in the infant when aminoglycosides a More ... |
| Breast Feeding |
| Active Ingredient | ATRACURIUM |
| Therapeutic Class | NEUROMUSCULAR BLOCKING AGENTS |
| Indications | Neuromuscular blockade (short to intermediate duration) for surgery and intubation. |
| Caution | Flushing; hypotension,Bronchospasm; hypersensitivity; skin reactions; tachycardia. |
| Dose Range | Initially 300–600 micrograms/kg, then (by intravenous injection) 100–200 micrograms/kg as required, alternatively (by intravenous injection) initially 300–600 micrograms/kg, followed by (by intravenous infusion) 300–600 micrograms/kg/hour. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | CISATRACURIUM |
| Therapeutic Class | NEUROMUSCULAR BLOCKING AGENTS |
| Indications | Neuromuscular blockade. |
| Caution | Bradycardia. |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | Discontinue breastfeeding until the mother has recovered from neuromuscular bloc More ... |
| Active Ingredient | PANCURONIUM BROMIDE |
| Therapeutic Class | NEUROMUSCULAR BLOCKING AGENTS |
| Indications | Usual drug of choice for major surgery and for use with long term ventilation of intensive care patients. |
| Caution |
Caution in hepatic and renal impairment. C.f. prescribing in renal disease p. 34. |
| Dose Range | i.v. 0.05-0.1mg/kg, then 0.01-0.02mg/kg as required. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | Discontinue breastfeeding until the mother has recovered from neuromuscular bloc More ... |
| Active Ingredient | SUXAMETHONIUM |
| Therapeutic Class | NEUROMUSCULAR BLOCKING AGENTS |
| Indications | Depolarising muscle relaxant of short duration (about 5 mins). Useful for endotracheal intubation |
| Caution | Tachycardia, apnoea, flushing. |
| Dose Range |
Adults and children: i.v. 0.5-2mg/kg dep ending on degree of relaxation required. c.f. prescribing in liver disease p. 18. |
| Drug Interactions | |
| Pregnancy | Mildly prolonged maternal neuromuscular blockade may occur. |
| Breast Feeding | Discontinue breastfeeding until the mother has recovered from neuromuscular bloc More ... |
| Active Ingredient | TIZANIDINE |
| Therapeutic Class | NEUROMUSCULAR BLOCKING AGENTS |
| Indications | Spasticity associated with multiple sclerosis and cerebrovascular or spinal cord disorders. |
| Caution | Drowsiness, muscle weakness, dry mouth, fatigue, insomnia, G.I. disturbances, dizziness. |
| Dose Range | Adult: 2-4mg three times daily . Maximum dose is 36mg daily. Safety has not been determined in children.See BDS supply protocols pg. 11. |
| Drug Interactions | |
| Pregnancy | Avoid Tizanidine during pregnancy. |
| Breast Feeding | Avoid breastfeeding during Tizanidine therapy. |
| Active Ingredient | PENTOXIFYLLINE |
| Therapeutic Class | HEMORRHEOLOGICS |
| Indications | Peripheral vascular disease. Pentoxifylline is indicated as an adjunct to surgery for treatment of intermittant claudication related to chronic occlusive arterial disease of the limbs. |
| Caution | May take 2-4 weeks to see onset of action. Hypotension, nausea, dizziness. |
| Dose Range | 400mg 2-3 times daily with meals. |
| Drug Interactions | |
| Pregnancy | Use with caution. |
| Breast Feeding | Pentoxifylline is distributed in breastmilk and is not recommended for lactating More ... |
| Active Ingredient | TRANEXAMIC ACID |
| Therapeutic Class | ANTIHEMORRHAGIC AGENTS |
| Indications | Treatment and prophylaxis of haemorrhage associated with excessive fibrinolysis. |
| Caution | Gastrointestinal disturbances, hypotension, dizziness, visual disturbances and musculoskeletal. |
| Dose Range | 1 to 1.5 g (or 15 to 25 mg/kg) 2 or 3 times daily . Slow intravenous injection: 0.5 to 1g 3 times daily (or 10 mg/kg is given 3 or 4 times daily ). |
| Drug Interactions | |
| Pregnancy | Manufacturer advises use only if potential benefit outweighs risk. |
| Breast Feeding |
| Active Ingredient | PROTAMINE SULPHATE |
| Therapeutic Class | ANTIHEPARIN |
| Indications | Treatment of heparin overdose.. |
| Caution |
Flushing, hypotension, bradycardia. Protamine sulfate is a weak anticoagulant and e +xcess amounts may worsen or trigger bleeding episodes. |
| Dose Range | 1mg neutralises 100 units of heparin when given within 15 minutes. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ABSORBABLE GELATIN |
| Therapeutic Class | HEMOSTATICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | AMINOCAPROIC ACID |
| Therapeutic Class | HEMOSTATICS |
| Indications | Increase Fibrinolysis. |
| Caution | Allergic reactions, chills, fever. |
| Dose Range |
Initial priming dose 4-5g during the first hour, followed at 1 hour intervals of 1-1.25g. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | FACTOR IX |
| Therapeutic Class | HEMOSTATICS |
| Indications | Treatment of Hemophilia B. |
| Caution | Hypersensitivity reactions. |
| Dose Range | Depends on the desired increase in plasma IX levels. To calculate dose take body weight in kg multiplied by 1iu/kg multip lied by the desired increase in plasma factor IX. |
| Drug Interactions | |
| Pregnancy | Use only if clearly needed. |
| Breast Feeding |
| Active Ingredient | FACTOR VIII |
| Therapeutic Class | HEMOSTATICS |
| Indications | Treatment of Hemophilia A. |
| Caution | Some patients develop antibodies. |
| Dose Range |
The dosage of factor VIII should be determined for each patient and will vary with the circumstances involving bleeding. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | FIBRINOGEN HUMAN |
| Therapeutic Class | HEMOSTATICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | AZELASTINE |
| Therapeutic Class | ANTIALLERGIC AGENTS |
| Indications | Allergic conjunctivitis. |
| Caution | Mild transient eye burning/stinging; bitter taste rep orted. |
| Dose Range |
Seasonal allergic conjunctivitis: Adult and Child over 4 years: Instill twice daily increased if necessary to 4 times daily . Perennial conjunctivitis: Adult and Child over 12 years: Instill twice daily , increased if necessary to 4 times daily ; |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | KETOTIFEN |
| Therapeutic Class | ANTIALLERGIC AGENTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | OLOPATADINE |
| Therapeutic Class | ANTIALLERGIC AGENTS |
| Indications | Allergic conjunctivitis. |
| Caution | Headache and stinging or burning of the eye. |
| Dose Range |
Adult and children 3 years and over: 0.1% twice daily ; 0.2% once daily . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | EMPAGLIFLOZIN|METFORMIN |
| Therapeutic Class | SODIUM GLUCOSE CO TRANSPORTER INHIBITOR |
| Indications | Indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) when treatment with both empagliflozin and metformin is appropriate |
| Caution | Lactic acidosis is a metabolic complication that can occur due to metformin accumulation during treatment and is fatal in ~50% of cases. Necrotizing fasciitis of the perineum (Fournier gangrene) repor More ... |
| Dose Range |
Take twice daily with meals (ie, divide total daily dose into 2 doses/day) For additional glycemic control, empagliflozin may be increased to maximum total daily dose of 25 mg in patients tolerating 10 mg/day and metformin may be increased to maximum total daily dose of 2,000 mg/day, with gradual escalation to reduce gastrointestinal adverse reactions with metformin. |
| Drug Interactions | |
| Pregnancy | Not recommended during second and third trimester of pregnancy based on animal d More ... |
| Breast Feeding | There is no information regarding presence in human milk, the effects on breastf More ... |
| Active Ingredient | GLIBENCLAMIDE |
| Therapeutic Class | SULPHONYLUREAS |
| Indications |
Diabetes Mellitus. More potent than chlorpropamide but shorter acting and not affected by renal failure. Half-life: 10 hours; Duration of Action: 24 hours. Glyburide is the micronised form More ... |
| Caution | Hypoglycemia: Occurs more commonly in elderly patients, even with low doses. It is best avoided in the elderly . c.f. prescribing in liver and renal disease p. 14; 30. |
| Dose Range |
2.5-5mg to a maximum of 20mg daily . Take with breakfast. See BDS supply protocols pg. 7. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |